Joan T Garrett (Samar Alanazi)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Replacement Therapy

Hypertrophic Cardiomyopathy

Signaling Pathway

Positive Breast Cancer

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PloS one 18 (5) (2023)
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PloS one 18 (5) (2023)
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PloS one 18 (5) (2023)
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett
HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers. PloS one 18 (5) (2023)
Mary Kate Kilroy, Briley SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Joan T Garrett, Joan T Garrett
HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 14 (24) (2022)
Mary Kate Kilroy, Briley SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Joan T Garrett, Joan T Garrett
HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 14 (24) (2022)
Rosalin Mishra, Hima Patel, Joan T Garrett, Mary Kate Kilroy, Joan T Garrett
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International journal of molecular sciences 22 (7) (2021)
Hima Patel, Rosalin Mishra, Nour Yacoub, Joan T Garrett, Mary Kate Kilroy, Joan T Garrett
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers 13 (22) (2021)